AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000549
Drug: estrogen replacement therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000549
Drug: hormone replacement therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04648033
Drug: Atovaquone Oral Suspension
RxNorm normalized name: Atovaquone Oral Suspension
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
Trial: NCT00000549
Drug: estrogens
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00433511
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00557830
Drug: Sorafenib Escalated Dose
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
Trial: NCT00557830
Drug: Sorafenib Standard Dose
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
Trial: NCT00758225
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
Trial: NCT00874042
Drug: Treatment with ARQ 197 in combination with gemcitabine
RxNorm normalized name: miconazole
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest.
Trial: NCT00496600
Drug: Patupilone
RxNorm normalized name: Patupilone
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
Trial: NCT01610999
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
Trial: NCT01125488
Drug: GnRH agonist (triptorelin)
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin 3.75 mg, sc q28day)
Trial: NCT00327080
Drug: L-NMMA
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01550653
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
Trial: NCT00834366
Drug: Tramadol HCl
RxNorm normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
Trial: NCT02587117
Drug: lycopene
RxNorm normalized name: Lycopene
DrugBank: Lycopene (DB11231)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
Trial: NCT02395172
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
Trial: NCT02395172
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
Trial: NCT00575393
Drug: gold sodium thiomalate
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Sodium aurothiomalate (DB09276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01454778
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose
Trial: NCT00512057
Drug: allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: allopurinol 300mg twice a day
Trial: NCT01300013
Drug: Omecamtiv mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
Trial: NCT01868542
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
Trial: NCT03751657
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
Trial: NCT03751657
Drug: Placebo (insulin 287)
RxNorm normalized name: Insulin 287
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
Trial: NCT03751657
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
Trial: NCT03751657
Drug: Dipeptidyl peptidase-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
Trial: NCT03751657
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
Trial: NCT03751657
Drug: Placebo (insulin glargine)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
Trial: NCT01930331
Drug: artemisinin/naphthoquine
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).
Trial: NCT02222168
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet
Trial: NCT00518011
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg po daily
Trial: NCT00518011
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed
Trial: NCT01930331
Drug: dihydroartemisinin/piperaquine phosphate
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
Trial: NCT03329014
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For induction and maintenance of sedation
Trial: NCT00090259
Drug: Losartan 50 mg
RxNorm normalized name: losartan 50 mg oral tablet
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-mg losartan oral tablet
Trial: NCT01685398
Drug: 0.5% timolol maleate eye drop
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00090259
Drug: Losartan 150 mg
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-mg losartan oral tablet + 50-mg losartan oral tablet
Trial: NCT00423202
Drug: ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03310060
Drug: Tisseel
RxNorm normalized name: Tisseel
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
Trial: NCT03310060
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
Trial: NCT02081755
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
Trial: NCT02081755
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
Trial: NCT02081755
Drug: Myfortic
RxNorm normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic®: 360 mg to 1080 mg BID for 12 months
Trial: NCT02081755
Drug: CellCept
RxNorm normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CellCept: 500 mg to 1500 mg BID for 12 months
Trial: NCT02081755
Drug: Imuran
RxNorm normalized name: Imuran
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mg/kg to 2 mg/kg QD for 12 months
Trial: NCT00483132
Drug: interferon alpha 2a
RxNorm normalized name: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a
DrugBank: QXL138AM (DB18552)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00038389
Drug: Vioxx
RxNorm normalized name: Vioxx
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
Trial: NCT01584804
Drug: Su-Huang antitussive capsule
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
Trial: NCT03387111
Drug: Aldoxorubicin HCl
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Aldoxorubicin (DB06013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldoxorubicin hydrochloride
Trial: NCT01584804
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
Trial: NCT03387111
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Trial: NCT03387111
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human anti-VEGF IgG1 monoclonal
Trial: NCT03387111
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
Trial: NCT03387111
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cis-diamminedichloroplatinum(II)
Trial: NCT03387111
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Trial: NCT03387111
Drug: Necitumumab
RxNorm normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Necitumumab is a recombinant human lgG1 monoclonal antibody.
Trial: NCT01239992
Drug: Niacin/ Laropiprant
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
Trial: NCT05279391
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 6-8 mg once daily
Trial: NCT05279391
Drug: Anakinra 100Mg/0.67Ml Inj Syringe
RxNorm normalized name: ANAKINRA 100MG/0.67ML INJ SYRINGE
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
Trial: NCT05279391
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration of Tocilizumab as a single dose of 8mg/kg
Trial: NCT05279391
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
Trial: NCT05279391
Drug: Dornase Alfa Inhalant Product
RxNorm normalized name: dornase alfa Inhalant Product
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inh. 2,500 U/twice daily, for up to 14 days.
Trial: NCT04427826
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
Trial: NCT00940667
Drug: Amlodipine plus Losartan
RxNorm normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine/losartan 5/50mg q.d.
Trial: NCT00940667
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5mg q.d.
Trial: NCT03140358
Drug: Atropine sulfate 0.01%
RxNorm normalized name: Atropine Sulfate 0.01% Ophthalmic drops, solution
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 0.01%
Trial: NCT03846739
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
Trial: NCT00029159
Drug: estrogen
RxNorm normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
Trial: NCT02775929
Drug: FTC-TDF PrEP
RxNorm normalized name: (-)-FTC
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FTC-TDF PrEP for HIV-1 uninfected partners
Trial: NCT02775929
Drug: ART
RxNorm normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART for HIV-1 infected partners
Trial: NCT00948220
Drug: peginterferon alfa-2a and ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
Trial: NCT03495609
Drug: Ovitrelle
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
Trial: NCT03511391
Drug: Nivolumab or Pembrolizumab or Atezolizumab
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: per national standard of care
Trial: NCT01049945
Drug: bendamustine hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01049945
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT01049945
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally or IV
Trial: NCT04518995
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Administered as tablets.
Trial: NCT02298335
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
Trial: NCT03610100
Drug: Acelarin
RxNorm normalized name: Acelarin
DrugBank: Fosgemcitabine palabenamide (DB15057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Trial: NCT03610100
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.